Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 79Lung Neoplasms 32Adenocarcinoma of Lung 13Adenocarcinoma, Bronchiolo-Alveolar 9Breast Neoplasms 8Neoplasm Metastasis 7Pancreatic Neoplasms 6Neoplasms 6Melanoma 6Stomach Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5Ovarian Neoplasms 5Esophageal Neoplasms 5Small Cell Lung Carcinoma 4Endometrial Neoplasms 4Colorectal Neoplasms 4Carcinoma, Ovarian Epithelial 4Urinary Bladder Neoplasms 3Pleural Effusion, Malignant 3Carcinoma, Renal Cell 3Thymoma 2Testicular Neoplasms 2Sarcoma 2Salivary Gland Neoplasms 2Prostatic Neoplasms 2Oropharyngeal Neoplasms 2Neoplasms, Unknown Primary 2Mouth Neoplasms 2Hypopharyngeal Neoplasms 2Head and Neck Neoplasms 2

Interventions

Bronchoscopy 2X-Rays 1Taxes 1Radiotherapy 1Radiation 1Paclitaxel 1Carboplatin 1Bevacizumab 1Argon Plasma Coagulation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hemoptysis × Taxes × Thoracic × Clear all
NCT00387374 2013-01-17

Radiation Therapy, Bevacizumab, Paclitaxel, and Carboplatin in Treating Patients With Unresectable Stage IIIB or Stage IV Non-Small Cell Lung Cancer at High Risk for Hemoptysis Caused by Bevacizumab

National Cancer Institute (NCI)

Phase 2 Completed
72 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Hemoptysis, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡